MICROMEDIOME Signs Strategic MCA with India’s ECDS to Accelerate Global Microbiome and Oncology R&D
- wonsucky
- Mar 27
- 1 min read
SEOUL, SOUTH KOREA – MICROMEDIOME Co., Ltd. announced today that it has entered into a Master Collaboration Agreement (MCA) with EFFIBAR CDS PRIVATE LIMITED (ECDS) of India. The signing ceremony, held on March 26, 2026, at the Korea University College of Medicine, marks a significant milestone in bringing innovative microbiome-based solutions to the global market.
Key Highlights of the Partnership
Global Market Expansion: Collaboration on the distribution and sales of MICROMEDIOME’s proprietary microbiome-based pharmaceuticals and healthcare products in the Indian market.
Joint R&D in Oncology: A strategic commitment to co-develop advanced oncology diagnostic technologies, leveraging the combined expertise of both organizations.
Investment & Funding: Agreement on a $1 million joint research grant to support high-impact R&D initiatives and a formal launch into the Indian market within this year.
This partnership combines MICROMEDIOME’s cutting-edge microbiome technology with ECDS’s robust global network. Beyond simple product export, the agreement formalizes a deep-tech collaboration in high-value sectors such as next-generation oncology diagnostics.